Hope is on the Horizon for PTSD Treatment

A study by Davis in JAMA Psychiatry published in December 2024 highlights a promising development for those affected by post-traumatic stress disorder (PTSD). A combination of brexpiprazole and sertraline has shown significant symptom relief in a phase 3 clinical trial, marking a potential breakthrough for treatment.

With 1 in 11 people diagnosed with PTSD in their lifetime—many of them women, veterans, and first responders—the need for effective treatment options is critical. If approved, this would be the first new pharmacologic treatment for PTSD in over 20 years, offering much-needed hope and relief for millions struggling with the condition.